ArticleBMC cancer2025
Peripheral blood cells predict the efficacy and prognosis of neoadjuvant immunotherapy combined with chemotherapy for esophageal squamous cell carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveSeveral studies have reported the prognostic significance of blood cells in patients with esophageal squamous cell carcinoma (ESCC); however, the relationship between blood cells and the efficacy and prognosis of neoadjuvant immunotherapy combined with chemotherapy in the treatment of ESCC has not been evaluated.In this study, we aimed to elucidate the predictive value of response and prognostic value of peripheral blood cells for neoadjuvant immunotherapy combined with chemotherapy in patients with ESCC.
methodsA total of 91 patients with ESCC (clinical stage II-IVA) who underwent neoadjuvant immunotherapy combined with chemotherapy (nICT) followed by surgery were enrolled in this study. A comparative analysis was performed to determine whether the pathological response after treatment was pathological complete response (PCR) and to establish the pathological regression grading.
resultsThe pathological complete response rate (PCR) was 22%, and more than half (52%) of the tumor regression grades assessed after neoadjuvant therapy responded well demonstrating significant tumor regression. A pathological complete response was strongly associated with the number of lymphocytes in the blood before treatment (p = 0.018). The efficacy response was strongly correlated with the number of erythrocytes in the blood before treatment (p = 0.011).Patients with a low red blood cell (RBC) count had a better 3-year disease free survival (DFS) than those with a high RBC(95.2% vs. 45.9%, P < 0.05).
conclusionsPretreatmentment Lymphocytes ≥ 1.845 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.